The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour-Reference-Cited by-同舟云学术

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

Published:2020-05-26 Issue:2 Volume:87 Page:326-335
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Westerdijk Kim¹^ORCID,Krens Stefanie D.²,Graaf Winette T.A.¹³,Mulder Sasja F.¹,Herpen Carla M.L.¹,Smilde Tineke⁴,Erp Nielka P.²^ORCID,Desar Ingrid M.E.¹

Affiliation:

1. Department of Medical Oncology, Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen Netherlands

2. Department of Pharmacy, Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen Netherlands

3. Department of Medical Oncology Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital Amsterdam Netherlands

4. Department of Medical Oncology Jeroen Bosch Hospital, ‘s Hertogenbosch Netherlands

Funder

KWF Kankerbestrijding

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14332

Reference35 articles.

1. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

2. Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

3. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

4. Committee for Medicinal Products for Human Use (CHMP) EMA. Sunitinib assessment report 2019 [Available from:https://www.ema.europa.eu/en/documents/variation-report/sutent-h-c-687-ii-0070-epar-assessment-report-variation_en.pdf.

5. US Food and Drug Administration Center for Drug Evaluation and Research. Sunitinib clinical pharmacology and biopharmaceutics review. 2006 [Available from:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_BioPharmR.pdf.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer;British Journal of Clinical Pharmacology;2024-08-06

2. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma;Clinical Genitourinary Cancer;2024-06

3. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes;ESMO Open;2024-06

4. Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis;Targeted Oncology;2024-05-18

5. Sacubitril/valsartan alleviates sunitinib-induced cardiac fibrosis and oxidative stress via improving TXNIP/TRX system and downregulation of NF-ĸB/Wnt/β-catenin/SOX9 signaling;International Immunopharmacology;2024-05